Evidence map›Paper›PMID 34184101›Full record

ArticleAnalytical and bioanalytical chemistry2021

DNA-only bioassay for simultaneous detection of proteins and nucleic acids.

Aida Montserrat Pagès, Saba Safdar, Karen Ven, Jeroen Lammertyn, Dragana Spasic

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Unraveling the Kinetics of the 10-23 RNA-Cleaving DNAzyme.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aida Montserrat PagèsDepartment of Biosystems, Biosensors Group, KU Leuven - University of Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium.
Saba SafdarDepartment of Biosystems, Biosensors Group, KU Leuven - University of Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium.
Karen VenDepartment of Biosystems, Biosensors Group, KU Leuven - University of Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium.
Jeroen LammertynDepartment of Biosystems, Biosensors Group, KU Leuven - University of Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium. jeroen.lammertyn@kuleuven.be.
Dragana SpasicDepartment of Biosystems, Biosensors Group, KU Leuven - University of Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium.

Funding

European Union's Horizon 2020 675412 (H2020-MSCA-ITN-ND4ID)Fonds Wetenschappelijk Onderzoek Research Project G042918NKU Leuven research project C3/20/057
6 · The paper itself

Abstract

Testing multiple biomarkers, as opposed to one, has become a preferred approach for diagnosing many heterogeneous diseases, such as cancer and infectious diseases. However, numerous technologies, including gold standard ELISA and PCR, can detect only one type of biomarker, either protein or nucleic acid (NA), respectively. In this work, we report for the first time simultaneous detection of proteins and NAs in the same solution, using solely functional NA (FNA) molecules. In particular, we combined the thrombin binding aptamer (TBA) and the 10-23 RNA-cleaving DNA enzyme (DNAzyme) in a single aptazyme molecule (Aptazyme

Indexed as

Biological AssayBiosensing TechniquesDNADNA, CatalyticHumansNanotechnologyNucleic AcidsReproducibility of ResultsThrombinDNADNA, CatalyticNucleic AcidsThrombinAptazymeCompetitive bioassayDNAzymeMultiplexingSimultaneous detection

Identifiers

PMID34184101
PMCPMC8238030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.